James

James WIlliams Dimerix BioscienceJames Williams BSc (Hons) PhD MBA

James has broad experience covering executive management of public and private companies, establishment, resourcing and financing start-up companies and hands-on research in molecular and cell biology.

James has been CEO of private and listed medical device companies Argus Biomedical Pty Ltd and Resonance Health Ltd (spin-out companies from the Lions Eye Institute and UWA respectively); in both cases he oversaw regulatory approvals and market launch of first products. He co-founded, is the former CEO and remains a Director of  GPCR drug discovery company Dimerix Biosciences Pty Ltd (a spin-out from the Western Australian Institute for Medical Research). In 2003, James conceived the business concept behind UWA spin-out iCeutica. He held various Executive and non-Executive roles with iCeutica until the company was sold in April 2011 for 10 times return on investment at the time of first financing.

Prior to becoming involved in technology commercialisation, James was a Senior Research Officer at WAIMR where he was researching the molecular and cellular biology of cancer. He has numerous publications in leading international journals and is named as inventor on patents covering a range of disciplines that are being prosecuted as part of Australian company’s technology portfolios. Noteworthy examples are patents describing iCeutica’s core technology for producing nano drugs, and the HLS5 tumour suppressor gene he cloned during post-doctoral studies and which is being commercialised by ASX-listed Biopharmica Ltd.

James is  a Director of Yuuwa investee companies AdAlta Pty Ltd,PolyActiva Pty Ltd and Eridan Technologies Pty Ltd, and an observer to the Board of FilterSquad Pty Ltd. He is a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund, a Director of Linear Clinical Research Ltd, an early stage clinical trials unit based in Perth, and a previous member of the Development Grant Review Panel for the National Health and Medical Research Council (NHMRC). James completed his Honours Degree in Biochemistry at Aberdeen University, Doctorate in Medicine at the University of Melbourne and Masters of Business Administration at the University of Western Australia.

James is a co-founder and Investment Director of Yuuwa Capital. He has a broad interest in the successful commercialisation of early stage technologies, with a particular focus on those stemming from the Life Sciences.